Beacon Pointe Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
Beacon Pointe Advisors's ARKG Position: Q1 2026 in Review
Beacon Pointe Advisors increased its ARK Genomic Revolution ETF (ARKG) stake by 2% in Q1 2026, buying an estimated $72.7K and bringing the position to 126,482 shares worth $3.34M. The position accounts for 0.02% of the portfolio, ranked #591.
Beacon Pointe Advisors first reported a position in ARKG in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.59M in Q4 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.
- Beacon Pointe Advisors held 126,482 shares of ARK Genomic Revolution ETF worth $3.34M as of Q1 2026.
- Beacon Pointe Advisors bought 2,483 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $72.7K.
- ARK Genomic Revolution ETF made up 0.02% of Beacon Pointe Advisors's portfolio in Q1 2026, its #591 holding.
- Beacon Pointe Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2025 and has held it in 5 quarters since.
- Beacon Pointe Advisors's ARK Genomic Revolution ETF position peaked at $3.59M in Q4 2025.
- 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.
Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.